BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, has received a notice of allowance for the patent application relating to its metabolic ThermoStem(R) program. The notice, dated Feb. 24, 2023, came from the United States Patent and Trademark Office. This marks the third patent approved relating to this specific group of intellectual property, the company noted; the new patent covers three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells, which have exhibited potential to be a valuable therapeutic tool for treating a range of metabolic disorders. The company also indicated that it is exploring options for using this technology to target indications outside of metabolic disorders. “This is the second notice of allowance we have received regarding our ThermoStem program within 2023,” said BioRestorative Therapies CEO Lance Alstodt in the press release. “This notice of allowance is very meaningful as it provides the company with further protection and strengthens our technology as we develop and expand into the clinic. Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities.”
To view the full press release, visit https://ibn.fm/IafGZ
About BioRestorative Therapies Inc.
BioRestorative Therapies develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its two core programs, which relate to the treatment of disc/spine disease and metabolic disorders, are the Disc/Spine Program (brtxDISC(TM)) and the Metabolic Program, or ThermoStem. For more information about the company, visit www.BioRestortive.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
